France - Sensorion (FR0012596468 - ALSEN) a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, today announces that Federico Mingozzi, Ph.D., is joining the Board of Directors of Sensorion as a Non-Executive Director by way of co-optation, effective as of today.
Dr. Federico Mingozzi previously worked at Spark Therapeutics, where he served as Chief Science and Technology Officer. Federico brings over 25 years of experience in gene therapy, immunology, as well as biochemistry and molecular biology in academia and industry. He is well known for his significant contributions to the development of gene therapies various diseases. Furthermore, he has played a key role in advancing our understanding of the interactions between gene therapy vectors and the host immune system, as well as in the formulation of strategies to overcome immune responses to anti-AAV vectors.
Federico has participated in numerous clinical trials targeting metabolic and neuromuscular diseases, hereditary blindness, and coagulation disorders.
Prior to joining Spark Therapeutics, Federico Mingozzi was Head of the Immunology and Liver Gene Transfer Unit at Genethon, Research Director at INSERM, the French National Institute of Health and Medical Research, and Director at the Children's Hospital of Philadelphia.
Federico holds a bachelor's degree in biology and his Ph.D. in biochemistry and molecular biology from the University of Ferrara in Italy, and his M.B.A. from Drexel University.
Khalil Barrage, ad interim Chair of Sensorion's Board of Directors, said: 'We are delighted to welcome Federico Mingozzi as new director. His pioneering research, contribution and recognized scientific success in the field of gene therapy will be extremely valuable to Sensorion.'
Dr Federico Mingozzi, Non-Executive Director of Sensorion, said: 'I am looking forward to joining Sensorion's Board of Directors and to using my experience to contribute to the development of Sensorion, a company recognized for its pioneering research in the development of gene therapies for hearing disorders. The development of this research represents an exciting challenge.'
About Sensorion
Sensorion is a pioneering clinical-stage biotech company, which specializes in the development of novel therapies to restore, treat and prevent hearing loss disorders, a significant global unmet medical need.
Sensorion has built a unique R&D technology platform to expand its understanding of the pathophysiology and etiology of inner ear related diseases, enabling it to select the best targets and mechanisms of action for drug candidates. It has two gene therapy programs aimed at correcting hereditary monogenic forms of deafness, developed in the framework of its broad strategic collaboration focused on the genetics of hearing with the Institut Pasteur. SENS-501 (OTOF-GT), currently being developed in a Phase 1/2 clinical trial, targets deafness caused by mutations of the gene encoding for otoferlin and GJB2-GT targets hearing loss related to mutations in GJB2 gene to potentially address important hearing loss segments in adults and children. The Company is also working on the identification of biomarkers to improve diagnosis of these underserved illnesses.
Sensorion's portfolio also comprises clinical-stage small molecule programs for the treatment and prevention of hearing loss disorders. Sensorion's clinical-stage portfolio includes one Phase 2 product: SENS-401 (Arazasetron) progressing in a planned Phase 2 proof of concept clinical study of SENS-401 in Cisplatin-Induced Ototoxicity (CIO) and, with partner Cochlear Limited, in a study of SENS-401 in patients scheduled for cochlear implantation. A Phase 2 study of SENS-401 was also completed in Sudden Sensorineural Hearing Loss (SSNHL) in January 2022.
Disclaimer
This press release contains certain forward-looking statements concerning Sensorion and its business. Such forward looking statements are based on assumptions that Sensorion considers to be reasonable. However, there can be no assurance that such forward-looking statements will be verified, which statements are subject to numerous risks, including the risks set forth in the 2022 full year financial report published on March 30, 2023, and available on our website and to the development of economic conditions, financial markets and the markets in which Sensorion operates. The forward-looking statements contained in this press release are also subject to risks not yet known to Sensorion or not currently considered material by Sensorion. The occurrence of all or part of such risks could cause actual results, financial conditions, performance or achievements of Sensorion to be materially different from such forward-looking statements. This press release and the information that it contains do not constitute an offer to sell or subscribe for, or a solicitation of an offer to purchase or subscribe for, Sensorion shares in any country. The communication of this press release in certain countries may constitute a violation of local laws and regulations. Any recipient of this press release must inform oneself of any such local restrictions and comply therewith.
Contact:
Noemie Djokovic
Email: ir.contact@sensorion-pharma.com
Pierre-Louis Germain
Tel: 00 33 (0)6 64 79 97 51
Email: plgermain@ulysse-communication.com
Nicolas Entz
Tel: 06 33 67 31 54
Email: nentz@ulysse-communication.com
SENSORION 
